Psychopharmacotherapy of posttraumatic stress disorder

Croatian Medical Journal

Volumn 49, Issue 4, 2008, Pages 459-475

  Kozarić Kovačić, Dragica ^a  

^a University of Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROFAROMINE; CITALOPRAM; CLONIDINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; INOSITOL; LAMOTRIGINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; OPIATE ANTAGONIST; PAROXETINE; PHENELZINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AGITATION; AKATHISIA; ANXIETY; ANXIETY DISORDER; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; MONOTHERAPY; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOTHERAPY; RESTLESSNESS; REVIEW; RIGOR; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; AFFECT; DRUG EFFECT; EDITORIAL;

AFFECT; ANTIDEPRESSIVE AGENTS; ANXIETY; HUMANS; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 55949093807     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2008.4.459     Document Type: Review

References (130)

1. American Psychiatric Association. Diagnostic statistical manual of mental disorders. Temporary revised 4th ed. Washington (DC): American Psychiatric Association Press; 2000.
2. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8:367-81.
3. Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry. 2004;161:195-216.
4. Nemeroff CB, Bremner JD, Foa EB, Mayberg HS, North CS, Stein MB. Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res. 2006;40:1-21.
5. Bremner JD. Traumatic stress: effects on the brain. Dialogues Clin Neurosci. 2006;8:445-61.
6. Pivac N, Kozarić-Kovačić D. Neurobiology of PTSD. In: Begec S, editor. The integration and management of traumatized people after terrorist attack. Amsterdam: IOS Press; 2007. p. 41-62.
7. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-9.
8. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry. 2001;49:1023-39.
9. Kaufman J, Plotsky PM, Nemeroff CB, Charney DS. Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry. 2000;48:778-90.
10. Vermetten E, Schmahl C, Lindner S, Loewenstein RJ, Bremner JD. Hippocampal and amygdalar volumes in dissociative identity disorder. Am J Psychiatry. 2006;163:630-6.
11. Morgan CA III, Southwick S, Hazlett G, Rasmusson A, Hoyt G, Zimolo Z, et al. Relationships among plasma dehydroepiandrosterone sulfate and cortisol levels, symptoms of dissociation, and objective performance in humans exposed to acute stress. Arch Gen Psychiatry. 2004;61:819-25.
12. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse. 1996;23:39-51.
13. Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL Jr, Mason JW. Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis. 1990;178:366-9.
14. Wang J, Rao H, Wetmore GS, Furlan PM, Korczykowski M, Dinges DF, et al. Perfusion functional MRI reveals cerebral blood flow pattern under psychological stress. Proc Natl Acad Sci U S A. 2005;102:17804-9.
15. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-8.
16. Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jeger M, Groll C, et al. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry. 2003;53:338-44.
17. van Praag HM. The cognitive paradox in posttraumatic stress disorder: a hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:923-35.
18. Askenazy F, Caci H, Myquel M, Darcourt G, Lecrubier Y. Relationship between impulsivity and platelet serotonin content in adolescents. Psychiatry Res. 2000;94:19-28.
19. Hamner MB, Gold PB. Plasma dopamine beta-hydroxylase activity in psychotic and non-psychotic post-traumatic stress disorder. Psychiatry Res. 1998;77:175-81.
20. Mustapic M, Pivac N, Kozaric-Kovacic D, Dezeljin M, Cubells JF, Muck-Seler D. Dopamine beta-hydroxylase (DBH) activity and 1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:1087-9.
21. Hageman I, Andersen HS, Jřgensen MB. Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiatr Scand. 2001;104:411-22.
22. Davidson JR. Biological therapies for posttraumatic stress disorder: an overview. J Clin Psychiatry. 1997;58 Suppl 9:29-32.
23. Brady KT. Posttraumatic stress disorder and comorbidity: recognizing the many faces of PTSD. J Clin Psychiatry. 1997;58 Suppl 9:12-5.
24. Kozaric-Kovacic D, Kocijan-Hercigonja D. Assessment of post-traumatic stress disorder and comorbidity. Mil Med. 2001;166:677-80.
25. Kozarić-Kovačić D, Pivac N. Novel approaches to the diagnosis and treatment of posttraumatic stress disorder. In: Begec S, editor. The integration and management of traumatized people after terrorist atack. Amsterdam: IOS Press; 2007. p. 13-40.
26. Frank JB, Kosten TR, Giller EL Jr, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry. 1988;145:1289-91.
27. Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A, et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry. 1989;146:513-6.
28. Davidson J, Kudler H, Smith R, Mahorney SL, Lipper S, Hammett E, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990;47:259-66.
29. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL Jr. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179:366-70.
30. Davidson JR, Kudler HS, Saunders WB, Erickson L, Smith RD, Stein RM, et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry. 1993;150:1024-9.
31. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res. 1988;24:149-55.
32. Katz RJ, Lott MH, Arbus P, Crocq L, Herlobsen P, Lingjaerde O, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety. 1994-1995;1:169-74.
33. Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick D, Keller T, et al. A double-blind, randomized, placebo-controlled, multi-centre study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl). 1995;122:386-9.
34. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994;55:517-22.
35. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999;175:17-22.
36. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry. 2000;12:101-5.
37. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283:1837-44.
38. Meltzer-Brody S, Connor KM, Churchill E, Davidson JR. Symptom-specific effects of fluoxetine in post-traumatic stress disorder. Int Clin Psychopharmacol. 2000;15:227-31.
39. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic post-traumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:860-8.
40. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158:1982-8.
41. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58:485-92.
42. Stein DJ, Davidson J, Seedat S, Beebe K. Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003;4:1829-38.
43. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001;16:197-203.
44. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003;18:1-8.
45. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159:1777-9.
46. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005;57:474-9.
47. Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008;69:520-5.
48. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226-9.
49. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990;51:236-8.
50. Kaplan Z, Amir M, Swartz M, Levine J. Inositol treatment of post-traumatic stress disorder. Anxiety. 1996;2:51-2.
51. Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis. 1989;177:546-50.
52. Lerer B, Bleich A, Kotler M, Garb R, Hertzberg M, Levin B. Posttraumatic stress disorder in Israeli combat veterans. Effect of phenelzine treatment. Arch Gen Psychiatry. 1987;44:976-81.
53. Davidson JR, Roth S, Newman E. Fluoxetine in posttraumatic stress disorder. J Trauma Stress. 1991;4:419-23.
54. De Boer M, Op den Velde W, Falger PJ, Hovens JE, De Groen JH, Van Duijn H. Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom. 1992;57:158-63.
55. Shay J. Fluoxetine reduces explosiveness and elevates mood of Vietnam combat veterans with PTSD. J Trauma Stress. 1992;5:97-101.
56. Nagy LM, Morgan CA III, Southwick SM, Charney DS. Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol. 1993;13:107-13.
57. Kline NA, Dow BM, Brown SA, Matloff JL. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1994;151:621.
58. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry. 1995;56:502-5.
59. Marmar CR, Schoenfeld F, Weiss DS, Metzler T, Zatzick D, Wu R, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1996;57 Suppl 8:66-72.
60. Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress. 1996;9:865-71.
61. Davidson JR, Weisler RH, Malik M, Tupler LA. Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol. 1998;18:93-5.
62. Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol. 1998;18:10-8.
63. Seedat S, Stein DJ, Ziervogel C, Middleton T, Kaminer D, Emsley RA, et al. Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J Child Adolesc Psychopharmacol. 2002;12:37-46.
64. Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry. 2006;67:1522-6.
65. Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986;27:849-54.
66. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988;23:642-4.
67. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991;52:361-4.
68. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry. 1991;148:1086-7.
69. Looff D, Grimley P, Kuller F, Martin A, Shonfield L. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry. 1995;34:703-4.
70. Macleod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol. 1996;16:190-1.
71. Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder. Can J Psychiatry. 2000;45:84.
72. Hamner MB. Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psychiatry. 1996;153:841.
73. Leyba CM, Wampler TP. Risperidone in PTSD. Psychiatr Serv. 1998;49:245-6.
74. Krashin D, Oates EW. Risperidone as an adjunct therapy for post-traumatic stress disorder. Mil Med. 1999;164:605-6.
75. Monnelly EP, Ciraulo DA. Risperidone effects on irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 1999;19:377-8.
76. Labbate LA, Douglas S. Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD). Can J Psychiatry. 2000;45:667-8.
77. Hamner MB, Deitsch SE, Ulmer HG. Quetiapine treatment in posttraumatic stress disorder: a preliminary open trial of add-on therapy. Poster presented at the annual meeting of the NCDEU; May 2001; Phoenix, AZ.
78. Petty F, Brannan PF, Casada J, Davis LL, Gajewski V, Kramer GL, et al. Olanzapine treatment for posttraumatic stress disorder: an open study. Int Clin Psychopharmacol. 2001;16:331-7.
79. Tomić Z, Kužina D, Kozarić-Kovačić D. Treatment of insomnia and nightmares in war veterans having posttraumatic stress disorder by short term therapy of clozapine. Psychiatria Danubina. 2001;13:118.
80. Filteau MJ, Leblanc J, Bouchard RH. Quetiapine reduces flashbacks in chronic posttraumatic stress disorder. Can J Psychiatry. 2003;48:282-3.
81. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003;23:15-20.
82. Sokolski KN, Denson TF, Lee RT, Reist C. Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil Med. 2003;168:486-9.
83. David D, De Faria L, Lapeyra O, Mellman TA. Adjunctive risperidone treatment in combat veterans with chronic PTSD. J Clin Psychopharmacol. 2004;24:556-9.
84. Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl). 2004;175:451-6.
85. Kozaric-Kovacic D, Pivac N, Muck-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry. 2005;66:922-7.
86. Kozarić-Kovačić D, Pivac N. Psychotic features of combat related chronic posttraumatic stress disorder and antipsychotic treatment. In: Roy MJ, editor. Novel approaches to the dignosis and treatment of posttraumatic stress disorder. Amsterdam: NATO IOS Press Security through Science Series, E: Human and Societal Dynamics; 2006. p. 42-58.
87. Kitchner I, Greenstein R. Low dose lithium carbonate in the treatment of post traumatic stress disorder: brief communication. Mil Med. 1985;150:378-81.
88. Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. Am J Dis Child. 1988;142:1244-7.
89. Brophy MH. Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder. Mil Med. 1991;156:100-1.
90. Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone. Am J Psychiatry. 1993;150:1430.
91. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993;30:255-63.
92. Hargrave R. Serotonergic agents in the management of dementia and posttraumatic stress disorder. Psychosomatics. 1993;34:461-2.
93. Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994;6:33-7.
94. Fichtner CG, Crayton JW. Buspirone in combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 1994;14:79-81.
95. Forster PL, Schoenfeld FB, Marmar CR, Lang AJ. Lithium for irritability in post-traumatic stress disorder. J Trauma Stress. 1995;8:143-9.
96. Horrigan JP, Barnhill LJ. The suppression of nightmares with guanfacine. J Clin Psychiatry. 1996;57:371.
97. Dow B, Kline N. Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Ann Clin Psychiatry. 1997;9:1-5.
98. Hamner MB, Frueh BC. Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. Int Clin Psychopharmacol. 1998;13:233-4.
99. Connor KM, Davidson JR, Weisler RH, Ahearn E. A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol. 1999;14:29-31.
100. Davidson JR, Weisler RH, Malik ML, Connor KM. Treatment of posttraumatic stress disorder with nefazodone. Int Clin Psychopharmacol. 1998;13:111-3.
101. Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JR. Open trial of nefazodone for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1998;59:460-4.
102. Hidalgo R, Hertzberg MA, Mellman T, Petty F, Tucker P, Weisler R, et al. Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol. 1999;14:61-8.
103. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2000;61 Suppl 5:60-6.
104. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Marshall RD, Nemeroff CB, et al. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 2004;65 Suppl 1:55-62.
105. Fichtner CG, Arora RC, O'Connor FL, Crayton JW. Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response. Life Sci. 1994;54:PL39-44.
106. Martenyi F, Brown EB, Caldwell CD. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed dose, placebo controlled study. J Clin Psychopharmacol. 2007;27:166-70.
107. Davidson JR, Malik ML, Sutherland SN. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int Clin Psychopharmacol. 1997;12:291-6.
108. Davis LL, English BA, Ambrose SM, Petty F. Pharmacotherapy for post-traumatic stress disorder: a comprehensive review. Expert Opin Pharmacother. 2001;2:1583-95.
109. Davidson JR. Long- term treatment and prevention of posttraumatic stress disorder. J Clin Psychiatry. 2004;65:44-8.
110. McEwen BS, Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. Eur Neuropsychopharmacol. 2004;14 Suppl 5:S497-502.
111. Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A. 2001;98:12796-801.
112. Coupland NJ. Brain mechanisms and neurotransmitters. In: Nutt DM, Davidson JR, Zohar J, editor. Post-traumatic stress disorder-diagnosis, management and treatment. London: Martin Dunitz; 2000. p. 69-100.
113. Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry. 2000;61:129-33.
114. Crocket BA, Davidson JRT. Pharmacotherapy for posttraumatic stress disorder. In: Stein DJ, Hollander E, editor. Textbook of anxiety disorders. Washington (DC): American Psychiatric Publishing, Inc.; 2002. p. 387-402.
115. Kolb LC, Burris BC, Griffith S. Propranolol and clonidine in the treatment of post-traumatic stress disorder of war. In: van der Kolk B, editor. Post-traumatic stress disorder: psychological and biological sequele. Washington (DC): American Psychiatric Press; 1984. p. 98-105.
116. Friedman MJ. Biological approaches to the diagnosis and treatment of posttraumatic stress disorder. J Trauma Stress. 1991;4:67-91.
117. Friedman MJ, Schnurr PP. The relationship between trauma, post-traumatic stress disorder, and physical health. In: Friedman MJ, Charney DS, Deutsch AY, editors. Neurobiological and clinical consequences. Philadelphia (PA): Lippincott-Raven; 2000. p. 507-24.
118. van der Kolk BA. The drug treatment of post-traumatic stress disorder. J Affect Disord. 1987;13:203-13.
119. Ahearn EP, Krohn A, Connor KM, Davidson JR. Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. Ann Clin Psychiatry. 2003;15:193-201.
120. Albucher RC, Liberzon I. Psychopharmacological treatment in PTSD: a critical review. J Psychiatr Res. 2002;36:355-7.
121. Hamner MB, Robert S, Frueh BC. Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectr. 2004;9:740-52.
122. Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol. 2007;10:253-61.
123. Glover H. Emotional numbing: a possible endorphin-mediated phenomenon associated with post-traumatic stress disorder and other allied psychopathological states. J Trauma Stress. 1992;5:643-75.
124. Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced post-traumatic stress disorder. J Clin Psychiatry. 1990;51:206-9.
125. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry. 1996;57:390-4.
126. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry. 2001;158:1184-90.
127. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: Diagnostic- and Symptom-Guided Drug Selection. 1. J Clin Psychiatry. 2008;e1-7. Epub ahead of print.
128. Meadows EA, Foa EB. Cognitive-behavioral treatment of traumatized adults. In: Saigh PA, Bremner JD, editor. Posttraumatic stress disorder: a comprehensive text. Needham Heights, (MA): Allyn and Bacon; 1999. p. 376-90.
129. Mayou RA, Ehlers A, Hobbs M. Psychological debriefing for road traffic accident victims. Three-year follow-up of a randomised controlled trial. Br J Psychiatry. 2000;176:589-93.
130. Penava SJ, Otto MW, Pollack MH, Rosenbaum JF. Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety. 1996-1997;4:240-2.